Last reviewed · How we verify

Fentanyl Plus Midazolam — Competitive Intelligence Brief

Fentanyl Plus Midazolam (Fentanyl Plus Midazolam) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid agonist + benzodiazepine combination. Area: Anesthesia, Analgesia, Palliative Care.

marketed Opioid agonist + benzodiazepine combination Mu opioid receptor (fentanyl); GABA-A receptor (midazolam) Anesthesia, Analgesia, Palliative Care Small molecule Live · refreshed every 30 min

Target snapshot

Fentanyl Plus Midazolam (Fentanyl Plus Midazolam) — Mount Carmel Health System. Fentanyl is an opioid agonist that binds mu receptors to provide analgesia and sedation, while midazolam is a benzodiazepine that enhances GABAergic inhibition in the central nervous system for anxiolysis and sedation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Fentanyl Plus Midazolam TARGET Fentanyl Plus Midazolam Mount Carmel Health System marketed Opioid agonist + benzodiazepine combination Mu opioid receptor (fentanyl); GABA-A receptor (midazolam)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid agonist + benzodiazepine combination class)

  1. Mount Carmel Health System · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fentanyl Plus Midazolam — Competitive Intelligence Brief. https://druglandscape.com/ci/fentanyl-plus-midazolam. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: